SGLT2i: Diabetes & Heart Failure

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are novel anti-diabetic drugs that lowers blood glucose. This feed focuses on the role of SGLT2i in diabetes and reducing heart failure.

September 21, 2021

In brief: Dapagliflozin (Farxiga) for chronic kidney disease.

The Medical Letter on Drugs and Therapeutics
September 20, 2021

Sodium-glucose co-transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: A meta-analysis.

Obesity Reviews : an Official Journal of the International Association for the Study of Obesity
John WongKenneth Lo
September 20, 2021

The Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Biomarkers in Patients with Type 2 Diabetes: a Post-Hoc Analysis.

Diabetes, Obesity & Metabolism
Jonathan M WilsonGiacomo Ruotolo
September 20, 2021
Review

Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management.

Curēus
Deepak VermaPalak Paudel
September 20, 2021

Pharmacist Intervention Lowers HgbA1c in Diabetic Patients Regardless of HIV Status.

Journal of Pharmacy Practice and Research : Official Journal of the Society of Hospital Pharmacists of Australia
Noelle E NelsonRebecca M Hluhanich
September 20, 2021

Structural Perspectives and Advancement of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes.

Current Diabetes Reviews
Shivani SharmaAnu Mittal
September 20, 2021

Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: a randomized controlled trial.

Diabetes & Metabolism
Vicente Hidalgo Rodrigues FernandesADDENDA-BHS2 trial investigators
September 18, 2021

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.

Diabetes Care
David D BergDavid A Morrow
September 18, 2021

Kidney Effects of Empagliflozin in People with Type 1 Diabetes.

Clinical Journal of the American Society of Nephrology : CJASN
David CherneyNima Soleymanlou
September 17, 2021
Preprint
Open Access

SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes trough mitigation of oxidative and ER stress

BioRxiv : the Preprint Server for Biology
Z. A. ShyrMaria S Remedi
September 17, 2021
Review

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.

Journal of Gastroenterology
Katsutoshi TokushigeKazuhiko Koike
September 17, 2021

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.

Hepatology Research : the Official Journal of the Japan Society of Hepatology
Katsutoshi TokushigeKazuhiko Koike
September 17, 2021

The Ongoing Evolution of Basal Insulin Therapy over 100 Years and its Promise for the Future.

Diabetes, Obesity & Metabolism
Ravi Retnakaran, Bernard Zinman
September 16, 2021

Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved.

Nature Reviews. Cardiology
Karina Huynh

Sign up to follow this feed and discover related papers.

Related Feeds

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused by a partial deletion of chromosome 22. Symptoms include heart defects, poor immune system function, a cleft palate, complications related to low levels of calcium in the blood, and delayed development. Discover the latest research on this disease here.

Aging & Diabetes

This feed focuses on the role of the aging process on developing diabetes.

Alagille Syndrome

Alagille syndrome is a multi-system genetic disorder that can affect the liver, heart, and other parts of the body. It’s characterization includes heart problems, liver damage, jaundice, and xanthomas. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aneurysm

Aneurysms are outward distensions or bulges that occurs in a weakened wall of blood vessels. Discover the latest research on aneurysms here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

© 2021 Meta ULC. All rights reserved
/feed-previews/sglt2i-diabetes-heart-failure/b6ef4aa4-e1e6-4998-8561-6ca6a15679bf